Framing the social in biomedical HIV prevention trials: A 20-year retrospective

Journal of the International AIDS Society

Volumn 14, Issue SUPPL. 2, 2011, Pages

  MacQueen, Kathleen M ^a  

^a FAMILY HEALTH INTERNATIONAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BIOMEDICINE; COMMUNITY CARE; DISEASE CONTROL; ETHICAL DECISION MAKING; HEALTH PROGRAM; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROPHYLAXIS; RETROSPECTIVE STUDY; REVIEW; SOCIAL STIGMA; SOCIOLOGY; VIRUS LOAD; VIRUS TRANSMISSION; CLINICAL TRIAL (TOPIC); EDITORIAL; ETHICS; FEMALE; HUMAN; MALE; PSYCHOLOGICAL ASPECT;

BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; FEMALE; HIV INFECTIONS; HUMANS; MALE; RETROSPECTIVE STUDIES; SOCIAL SCIENCES;

EID: 80053339966     PISSN: None     EISSN: 17582652     Source Type: Journal    
DOI: 10.1186/1758-2652-14-S2-S3     Document Type: Review

References (51)

1. Prevention of HIV/AIDS with vaccines. Vermund SH, Schultz AM, Hoff R, Current Opinion in Infectious Diseases 1994 7 82 94 10.1097/00001432-199402000- 00014 (Pubitemid 24052339)
2. HIV vaccine trials in Africa. Sandström E, Birx D, AIDS 2002 16 Suppl 4 89 S95 12699005
3. Past, present and future of HIV vaccine trials in developing countries. Esparza J, Saladin O, Pattou-Markevic C, Coumba T, Chang ML, Nixon S, Vaccine 2002 20 1897 1898 10.1016/S0264-410X(02)00062-2 11983240 (Pubitemid 34450782)
4. The-Wayward Search for an AIDS Vaccine. Cohen J, Shots in the Dark, New York: W.W. Norton & Company 2001
5. Weighing the gold in the gold standard: challenges in HIV prevention research. Radian NS, McCoy S, Balkus J, Wasserheit J, AIDS 2010 24 621 635 10.1097/QAD.0b013e328337798a 20179575
6. Cultural Diversity and the Search for Ethical Universals in Medicine. Macklin R, Against Relativism, New York: Oxford University Press 1999
7. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, Goicochea R, Casapía M, Guanira-Carranza JV, Ramirez-Cardich ME, Montoya-Herrera O, Fernández T, Veloso VG, Buchbinder SR, Chariyalertsak S, Schechter M, Bekker LG, Mayer KH, Kallás EG, Amico KR, Mulligan K, Bushman LR, Hance RJ, Ganoza C, Defechereux P, Postle B, Wang F, McConnell JJ, Zheng JH, Lee J, Rooney JF, Jaffe HS, Martinez Al, Burns DN, Glidden DV, iPrEx Study Team, N Engl J Med 2010 363 2587 2599 10.1056/NEJMoa1011205 21091279
8. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Abdool Karim Q, Abdool Karim SS, Frohlich JA, Grobler AC, Baxter C, Mansoor LE, Kharsany AB, Sibeko S, Mlisana KP, Omar Z, Gengiah TN, Maarschalk S, Arulappan N, Mlotshwa M, Morris L, Taylor D, CAPRISA 004 Trial Group, Science 2010 329 1168 1174 10.1126/science.1193748 20643915
9. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, Premsri N, Namwat C, de Souza M, Adams E, Benenson M, Gurunathan S, Tartaglia J, McNeil JG, Francis DP, Stablein D, Birx DL, Chunsuttiwat S, Khamboonruang C, Thongcharoen P, Robb ML, Michael NL, Kunasol P, Kim JH, MOPH-TAVEG Investigators, N Engl J Med 2009 361 2209 2220 10.1056/NEJMoa0908492 19843557
10. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A, PLoS medicine 2005 2 11 298 e298 10.1371/journal.pmed.0020298 16231970 (Pubitemid 41735779)
11. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, Williams CFM, Campbell RT, Ndinya-Achola JO, Lancet 2007 369 643 656 10.1016/S0140-6736(07)60312-2 17321310 (Pubitemid 46281312)
12. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, Kiwanuka N, Moulton LH, Chaudhary MA, Chen MZ, Sewankambo NK, Wabwire-Mangan F, Bacon MC, Williams CFM, Opendi P, Reynolds SJ, Laeyendecker O, Quinn TC, Wawer MJ, Lancet 2007 369 657 666 10.1016/S0140-6736(07)60313-4 17321311
13. Prevention of mother-to-child HIV transmission in resource-poor countries: translating research into policy and practice. De Cock KM, Fowler MG, Mercier E, de Vincenzi I, Saba J, Hoff E, Alnwick AJ, Rogers M, Shaffer N, JAMA 2000 283 1175 1182 10.1001/jama.283.9.1175 10703780 (Pubitemid 30126606)
14. HIV treatment dramatically prevents heterosexual transmission. Cohen J, 2011 Science Insider http://news.sciencemag.org/scienceinsider/2011/05/hiv- treatment-dramatically-preve.html
15. Stigma: notes on the management of a spoiled identity. Goffman E, New York: Simon and Schuster 1963
16. HIV-related stigma, discrimination and human rights violations: case studies of successful programmes. UNAIDS, Geneva: UNAIDS 2005
17. AIDS and stigma. Herek GM, American Behavioral Scientist 1999 42 1102 1112
18. Principles of Biomedical Ethics. Beauchamp TL, Childress JF, New York: Oxford University Press Fifth 2001
19. The developing world as the answer to the dreams of pharmaceutical companies: the Surfaxin story. Lurie P, Wolfe SM, Ethical Issues in International Biomedical Research Oxford University Press, Oxford, Lavery JV, Grady C, Wahi ER, Emanuel EJ, 2007 59 170
20. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. Lurie P, Wolfe SM, N Engl J Med 1997 337 853 856 10.1056/NEJM199709183371212 9295246 (Pubitemid 27391640)
21. AIDS clinical trials. More woes for novel HIV prevention approach. Cohen J, Science 2005 307 1708 15774735 (Pubitemid 40388590)
22. Ethical Considerations in Biomedical HIV Prevention Trials. UNAIDS, WHO, Geneva: UNAIDS 2007
23. Good participatory practice: guidelines for biomedical HIV prevention trials. UNAIDS, AVAC, Gene: UNAIDS 2007
24. Deep Hanging Out. Geertz C, New York Review of Books 1998
25. Guidelines to the writing of case studies. Budgell B, J Can Chiropr Assoc 2008 52 4 199 204 19066690
26. How to write a patient case report. Cohen H, Am J Health-Syst Pharm 2006 63 1888 1892 10.2146/ajhp060182 16990637 (Pubitemid 44477462)
27. Sexual pleasure, gender power and microbicide acceptability in Zimbabwe and Malawi. Woodsong C, Alleman P, AIDS Education and Prevention 2008 20 171 187 10.1521/aeap.2008.20.2.171 18433322 (Pubitemid 351679862)
28. A dynamic social systems model for considering structural factors in HIV prevention and detection. Latkin C, Weeks MR, Glasman L, Galletly C, Albarracin D, AIDS Behav 2010 14 222 S238 10.1007/s10461-010-9804-y
29. Microbicides 2008 conference: from discovery to advocacy. Ramjee G, Doncel GF, Mehendale S, Tolley EE, Dickson K, AIDS Research and Therapy 2008 5 19 10.1186/1742-6405-5-19 18702834
30. A Mixed Methods and Triangulation Model for Increasing the Accuracy of Adherence and Sexual Behaviour Data: The Microbicides Development Programme. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Crook A, Nunn A, Hayes R, McCormack S, PLoS ONE 2010 5 7 11600 10.1371/journal.pone.0011600 20657778
31. Assessing the Accuracy of Adherence and Sexual Behaviour Data in the MDP301 Vaginal Microbicides Trial Using a Mixed Methods and Triangulation Model. Pool R, Montgomery CM, Morar NS, Mweemba O, Ssali A, Gafos M, Lees S, Stadler J, Nunn A, Crook A, Hayes R, McCormack S, PLoS ONE 2010 7 11632
32. Microbicide trials for preventing HIV/AIDS in South Africa: phase II trial participants experiences and psychological needs. Pistorius A, van de Wijgert J, Sebola MH, Friedland BA, Nagel E, Bokaba C, Hoosen A, Journal of Social Aspects of HIV/AIDS 2004 1 78 86 17601013
33. Utilizing geographic information systems (GIS) to enhance recruitment for HIV prevention clinical trials. Parker C, Cornell A, Mtimkulu V, Ahmed K, Agot K, Odhiambo J, Wong C, Lanham M, International Microbicides Conference; May; Pittsburgh, Pennsylvania USA 2010 Abstract TUPEO759
34. Comparison of socio-behavioral formative data at two sites in advance of the FEM-PrEP clinical trial. Johnson L, Agot K, Mtimkulu V, Murphy J, Parker C, McKenna K, Wong C, Lanham M, Ahmed K, Corneli A, International Microbicides Conference; May; Pittsburgh, Pennsylvania, USA 2010 Abstract THPE0534
35. Socio-behavioral and community activities for an Oral HIV prevention PrEF clinical trial: a multi-disciplinary approach. Cornell A, Mack N, Kirkendale S, the Truvada SBC Investigator, FHI Group, International Microbicides Conference; February; New Delhi, India 2008 Abstract 588
36. Antiretroviral (ARV) pre-exposure prophylaxis (PrEF) program design: challenges to clients fulfilling likely requirements for an ARV PrEP program. Mack N, Parker C, McKenna K, Odhiambo J, Wong C, Johnson L, XVII International AIDS Conference, July; Vienna, Austria 2010 Abstract CDC0613
37. Microbicide research in developing countries: have we given the ethical concerns due consideration? Moodley K, BMC Medical Ethics 2007 8 10 10.1186/1472-6939-8-10 17877834 (Pubitemid 350145377)
38. Womens autonomy and informed consent in international microbicide clinical trials. Woodsong C, MacQueen K, Namey E, Sahay S, Mlingo M, Morrar N, Mehendale S, Journal of Empirical Research on Human Research Ethics 2006 1 11 26 19385819
39. Ethics and the ethnography of medical research in Africa. Molyneux S, Wenzel Geissler PW, Social Science & Medicine 2008 67 685 695 10.1016/j.socscimed.2008.02.023 21922346
40. The exploitation of exploitation in the Tenofovir PrEP Trial in Cameroon: Lessons learned from media coverage of an HIV prevention trial. Mack N, Robinson ET, MacQueen KM, Moffett J, Johnson LM, Journal of Empirical Research on Human Research Ethics 2010 5 3 19 21133782
41. Community perspectives on care options for HIV prevention trial participants. MacQueen KM, Namey E, Chilongozi DA, Mtweve SP, Mlingo M, Morar N, Reid C, Ristow A, Sahay S, The HPTN Standard of Care Assessment Team, AIDS Care 2007 19 554 560 10.1080/09540120601035284 17453597 (Pubitemid 46598754)
42. Community consultation in HIV prevention research: a study of community advisory boards at 6 research sites. Morin SF, Maiorana A, Koester KA, Sheon NM, Richards TA, J AIDS 2003 33 513 520 (Pubitemid 36886081)
43. Randomized, controlled evaluation of a prototype informed consent process for HIV vaccine efficacy trials. Coletti AS, Heagerty P, Sheon AR, Gross M, Koblin BA, Metzger DS, Seage GR III, HIVNET VPS Protocol Team, JAIDS 2003 32 161 169 10.1097/00126334-200302010-00008 12571526 (Pubitemid 36222718)
44. Standards of Prevention in HIV Prevention Trials: Consultaion Report and Recommendations. McGrory E, Philpott S, Hankins C, Paxton L, Heise L, Washington, DC: Global Campaign for Microbicides at PATH 2010
45. Lack of success terminates study in Africa of AIDS prevention in women. McNeil DG, The New York Times 2011 10
46. Sexual and reproductive health: a matter of life and death. Glasier A, Gülmezoglu, Schmid GP, Garcia Moreno C, Van Look PFA, The Lancet 2006 368 1595 1607 10.1016/S0140-6736(06)69478-6 (Pubitemid 44691893)
47. Social aspects of antiretroviral therapy scale-up: introduction and overview. Hirsch JS, Parker RG, Aggleton P, AIDS 2007 21 1 S4 18040160
48. Investing in surprise. McEnery R, IAVI Report 2010 11 15
49. Coming to terms with complexity: a call to action for HIV prevention. Piot P, Bartos M, Larson H, Zewdie D, Mane P, The Lancet 2008 372 845 859 10.1016/S0140-6736(08)60888-0
50. Biomedical HIV preventionand social science. Imrie J, Elford J, Kippax S, Hart GJ, The Lancet 2007 370 10 11 10.1016/S0140-6736(07)61026-5 (Pubitemid 47023097)
51. The multiple layers of prevention science research. MacQueen KM, Sates W, American Journal of Preventive Medicine 2005 28 491 495 10.1016/j.amepre.2005. 02.020 15894154 (Pubitemid 40719051)